Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Thursday 30 July, 2020

Feedback PLC

Bleepa appointed to major NHSx framework

RNS Number : 6621U
Feedback PLC
30 July 2020

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.


Feedback plc


Bleepa ® to lead clinical communications revolution through appointment to major NHSx framework


NHSx Clinical Communication Tool Framework endorses Bleepa and provides route to payment

The Directors believe that as the only CE marked product for digital patient imaging on the framework Bleepa is the only provider that can deliver digital imaging as part of the communication service


London, 30 July 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that its flagship imaging-based communication platform, Bleepa, has been awarded a place on the NHSx National Clinical Communication Tool Framework ("the NCCT Framework"). Bleepa is a clinical communications platform that combines access to review quality medical imaging alongside instant messaging and video calling in one CE marked, zero footprint, medical device.


The NCCT Framework provides a vehicle for NHS Trusts to buy Bleepa by drawing down from a £3 million centralised fund over a two year period. It gives Bleepa national coverage and provides an independent validation of the quality and suitability of Bleepa for frontline delivery, a stamp of approval that the Company can use to also drive sales in other markets.


The Directors believe that as the only CE marked medical device relating to medical imaging on the NCCT Framework, Bleepa is the only supplier able to deliver digital patient imaging for diagnostic purposes alongside clinical messaging. The Directors believe that Bleepa's simple messaging exchange will offer considerable benefit to clinicians and Trusts, enabling the NHS to purge the pager and replace it with a truly transformative solution that brings medical imaging into routine communication.



Dr Tom Oakley, CEO of Feedback, commented:


"Bleepa has set a new standard for medical communication tools. I am delighted Bleepa has been awarded a place on the NHSx Clinical Communication Tool framework which positions Bleepa in the vanguard of medical imaging communications and provides a vehicle for potential reimbursement whilst simultaneously making Bleepa available to the whole of the NHS."



#  #  #



Below is the full announcement made today by NHSx:


Clinical Communications Procurement Framework

The Procurement Framework aims to support NHS organisations with dedicated clinical facing communication and tasks management tools, to accelerate the adoption of proven technologies and to phase out pagers by the end of 2021.


The framework has been designed to provide a compliant and convenient route to market for all NHS organisations.


It allows clinicians to access a wide range of communication tools all under one procurement framework agreement. Participating authorities have the freedom and flexibility to make a direct award or undertake a mini-competition to meet the bespoke requirement of each customer.


The suppliers have been assessed to ensure that they meet all legislative requirements; therefore no formal tendering is required, saving valuable time and money in the procurement process. The framework contains large national companies but also a healthy number of regional SMEs, and all can showcase their products via the framework, helping buyers to make informed local decisions.


Framework date and duration


3 August 2020 to 3 August 2022. Possible further extension for 12 months.


Further information is available on the NHSx website at









Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

[email protected]



Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656



Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936



Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880



Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

+44 (0)20 7457 2020

+44 7890 022 814

[email protected]


Notes to editors


About Bleepa


Bleepa provides instant and remote access to clinical grade medical images through a zero footprint application.  The majority of patient cases require medical imaging which can be seamlessly shared to the entire clinical team through Bleepa.  Cases can be discussed through its secure instant messaging and image annotation, allowing comments and treatment decisions to be communicated instantly between team members.  Bleepa can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.


About Feedback plc -


Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully owned trading subsidiary, Feedback Medical Limited.  Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.


Feedback has launched Bleepa, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS).  For more information on Bleepa, see




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t